---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004508"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:54:37.070101+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M

## Summary
- Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.
- John Duke (current board member) appointed CEO effective July 28; base salary $480K, 500k RSU grant.
- Rob Gagnon and Seth Benson appointed to Board; Gagnon to chair Audit and Compensation committees.
- Preliminary Q2 2025 revenue of $20.4 million; gross margin guidance reiterated at 55%-57%.
- Full Q2 2025 financial results expected to be reported on August 11, 2025.

## SEC filing metadata
- accession: 0001171843-25-004508
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325004508/0001171843-25-004508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325004508/f8k_071725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004508
- JSON: https://secwatch.observer/filing/0001171843-25-004508.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.